Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Blood Transfusion Center, Innsbruck, Austria.
Transpl Int. 2023 Mar 2;36:11062. doi: 10.3389/ti.2023.11062. eCollection 2023.
A positive crossmatch (XM+) is considered a contraindication to solid abdominal organ transplantation except liver transplantation (LT). Conflicting reports exist regarding the effects of XM+ on post-transplant outcomes. The goal of this retrospective single-center analysis is to evaluate the influence of XM+ on relevant outcome parameters such as survival, graft rejection, biliary and arterial complications. Forty-nine adult patients undergoing LT with a XM+ between 2002 and 2017 were included. XM+ LT recipients were matched 1:2 with crossmatch negative (XM-) LT recipients based on the balance of risk (BAR) score. Patient and graft survival were compared using Kaplan-Meier survival analysis and the log-rank test. Comparative analysis of clinical outcomes in XM+ and XM- groups were conducted. Patient and graft survival were similar in XM+ and XM- patients. Rejection episodes did not differ either. Recipients with a strong XM+ were more likely to develop a PCR+ CMV infection. A XM+ was not associated with a higher incidence of biliary or arterial complications. Donor age, cold ischemia time, PCR+ CMV infection and a rejection episode were associated with the occurrence of ischemic type biliary lesions. A XM+ has no effects on patient and graft survival or other relevant outcome parameters following LT.
阳性交叉配型(XM+)除肝移植(LT)外,被认为是实体腹部器官移植的禁忌。关于 XM+对移植后结局的影响,存在相互矛盾的报告。本回顾性单中心分析的目的是评估 XM+对相关结局参数的影响,如存活率、移植物排斥、胆道和动脉并发症。纳入了 2002 年至 2017 年间接受 LT 且 XM+的 49 例成年患者。根据风险平衡(BAR)评分,XM+LT 受者与 XM- LT 受者 1:2 匹配。采用 Kaplan-Meier 生存分析和对数秩检验比较 XM+和 XM-患者的生存情况。对 XM+和 XM-组的临床结局进行了对比分析。XM+和 XM-患者的生存率和移植物存活率相似。排斥反应也没有差异。强 XM+的受者更有可能发生 PCR+CMV 感染。XM+与胆道或动脉并发症的发生率增加无关。供体年龄、冷缺血时间、PCR+CMV 感染和排斥反应与缺血性胆管病变的发生有关。XM+对 LT 后的患者和移植物存活率或其他相关结局参数没有影响。